Literature DB >> 19957346

Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms.

Kebede Hussein, Omar Abdel-Wahab, Terra L Lasho, Daniel L Van Dyke, Ross L Levine, Curtis A Hanson, Animesh Pardanani, Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19957346      PMCID： PMC4654625          DOI： 10.1002/ajh.21562

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  13 in total

1.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23).

Authors:  R B Lorsbach; J Moore; S Mathew; S C Raimondi; S T Mukatira; J R Downing
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

2.  Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.

Authors:  Kebede Hussein; Jocelin Huang; Terra Lasho; Animesh Pardanani; Ruben A Mesa; Cynthia M Williamson; Rhett P Ketterling; Curtis A Hanson; Daniel L Van Dyke; Ayalew Tefferi
Journal:  Eur J Haematol       Date:  2008-02-10       Impact factor: 2.997

Review 3.  Conventional cytogenetics in myelofibrosis: literature review and discussion.

Authors:  Kebede Hussein; Daniel L Van Dyke; Ayalew Tefferi
Journal:  Eur J Haematol       Date:  2009-01-09       Impact factor: 2.997

4.  The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders.

Authors:  G W Dewald; D J Broderick; W W Tom; J E Hagstrom; R V Pierre
Journal:  Cancer Genet Cytogenet       Date:  1985-09

5.  The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  Hematol J       Date:  2000

6.  LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23).

Authors:  Ryoichi Ono; Tomohiko Taki; Takeshi Taketani; Masafumi Taniwaki; Hajime Kobayashi; Yasuhide Hayashi
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

8.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

9.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Authors:  A Tefferi; R L Levine; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; C M Finke; A Mullally; C-Y Li; A Pardanani; D G Gilliland
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

10.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245
View more
  8 in total

1.  Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms.

Authors:  Joseph Tripodi; Ronald Hoffman; Vesna Najfeld; Rona Weinberg
Journal:  Cancer Manag Res       Date:  2010-09-17       Impact factor: 3.989

Review 2.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

3.  Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.

Authors:  John Mascarenhas; Nitin Roper; Pratima Chaurasia; Ronald Hoffman
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

4.  Coordination of engineered factors with TET1/2 promotes early-stage epigenetic modification during somatic cell reprogramming.

Authors:  Gengzhen Zhu; Yujing Li; Fei Zhu; Tao Wang; Wensong Jin; Wei Mu; Wei Lin; Weiqi Tan; Wenqi Li; R Craig Street; Siying Peng; Jian Zhang; Yue Feng; Stephen T Warren; Qinmiao Sun; Peng Jin; Dahua Chen
Journal:  Stem Cell Reports       Date:  2014-02-27       Impact factor: 7.765

5.  TET2 missense variants in human neoplasia. A proposal of structural and functional classification.

Authors:  Elena Bussaglia; Rosa Antón; Josep F Nomdedéu; Pablo Fuentes-Prior
Journal:  Mol Genet Genomic Med       Date:  2019-06-11       Impact factor: 2.183

6.  TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances.

Authors:  Wei Zhang; Zong-Hong Shao; Rong Fu; Hua-Quan Wang; Li-Juan Li; Jun Wang; Wen Qu; Yong Liang; Guo-Jin Wang; Xiao-Ming Wang; Yuhong Wu; Hong Liu; Jia Song; Jing Guan; Li-Min Xing
Journal:  Cancer Biol Med       Date:  2012-03       Impact factor: 4.248

7.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037

8.  Driver mutations of cancer epigenomes.

Authors:  David M Roy; Logan A Walsh; Timothy A Chan
Journal:  Protein Cell       Date:  2014-03-14       Impact factor: 14.870
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.